46 related articles for article (PubMed ID: 23611778)
1. Aspirin overcomes Navitoclax-resistance in hepatocellular carcinoma cells through suppression of Mcl-1.
Li G; Zhang S; Fang H; Yan B; Zhao Y; Feng L; Ma X; Ye X
Biochem Biophys Res Commun; 2013 May; 434(4):809-14. PubMed ID: 23611778
[TBL] [Abstract][Full Text] [Related]
2. Bcl-2/Bcl-xL inhibition predominantly synergistically enhances the anti-neoplastic activity of a low-dose CUSP9 repurposed drug regime against glioblastoma.
Halatsch ME; Kast RE; Dwucet A; Hlavac M; Heiland T; Westhoff MA; Debatin KM; Wirtz CR; Siegelin MD; Karpel-Massler G
Br J Pharmacol; 2019 Sep; 176(18):3681-3694. PubMed ID: 31222722
[TBL] [Abstract][Full Text] [Related]
3. Combination p53 activation and BCL-x
Bell HL; Blair HJ; Jepson Gosling SJ; Galler M; Astley D; Moorman AV; Heidenreich O; Veal GJ; van Delft FW; Lunec J; Irving JAE
Leukemia; 2024 Jun; 38(6):1223-1235. PubMed ID: 38600316
[TBL] [Abstract][Full Text] [Related]
4. Combination of navitoclax (Bcl-2 and Bcl-xL inhibitor) and Debio-0932 (Hsp90 inhibitor) suppresses the viability of prostate cancer cells via induction of apoptotic signaling pathway.
Asdemir A; Özgür A
Med Oncol; 2024 Mar; 41(4):83. PubMed ID: 38436810
[TBL] [Abstract][Full Text] [Related]
5. Dual targeting Bcl-2 and Bcl-xL augments osteosarcoma response to doxorubicin.
Cao C; Pei Y; Yu H; Qi H
J Chemother; 2024 Apr; 36(2):156-166. PubMed ID: 37309095
[TBL] [Abstract][Full Text] [Related]
6. NS398 inhibits the growth of Hep3B human hepatocellular carcinoma cells via caspase-independent apoptosis.
Park MK; Hwang SY; Kim JO; Kwack MH; Kim JC; Kim MK; Sung YK
Mol Cells; 2004 Feb; 17(1):45-50. PubMed ID: 15055526
[TBL] [Abstract][Full Text] [Related]
7. Galacto-conjugation of Navitoclax as an efficient strategy to increase senolytic specificity and reduce platelet toxicity.
González-Gualda E; Pàez-Ribes M; Lozano-Torres B; Macias D; Wilson JR; González-López C; Ou HL; Mirón-Barroso S; Zhang Z; Lérida-Viso A; Blandez JF; Bernardos A; Sancenón F; Rovira M; Fruk L; Martins CP; Serrano M; Doherty GJ; Martínez-Máñez R; Muñoz-Espín D
Aging Cell; 2020 Apr; 19(4):e13142. PubMed ID: 32233024
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous inhibition of Chk1 and Bcl-xL induces apoptosis
Morimoto Y; Takada K; Takeuchi O; Watanabe K; Hirohara M; Masuda Y
J Chemother; 2023 Sep; 35(5):435-447. PubMed ID: 36134604
[TBL] [Abstract][Full Text] [Related]
9. The Small Glutathione Peroxidase Mimic 5P May Represent a New Strategy for the Treatment of Liver Cancer.
Yin J; Wang B; Zhu X; Qu X; Huang Y; Lv S; Mu Y; Luo G
Molecules; 2017 Sep; 22(9):. PubMed ID: 28885589
[TBL] [Abstract][Full Text] [Related]
10. Evidence of a novel antiapoptotic factor: role of inhibitor of differentiation or DNA binding (Id-1) in anticancer drug-induced apoptosis.
Zhang X; Ling MT; Wong YC; Wang X
Cancer Sci; 2007 Mar; 98(3):308-14. PubMed ID: 17214747
[TBL] [Abstract][Full Text] [Related]
11. Antineoplastic Drug Synergy of Artesunate with Navitoclax in Models of High-Grade Serous Ovarian Cancer.
McCorkle JR; Ahn R; Cao CD; Hill KS; Dietrich CS; Kolesar JM
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610999
[TBL] [Abstract][Full Text] [Related]
12. Emergence of aspirin as a promising chemopreventive and chemotherapeutic agent for liver cancer.
Xia H; Hui KM
Cell Death Dis; 2017 Oct; 8(10):e3112. PubMed ID: 29022914
[No Abstract] [Full Text] [Related]
13. Cyclooxygenase and Cancer: Fundamental Molecular Investigations.
Coluccia M
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569718
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the role of m6A and lncRNAs in prognosis and immunotherapy of hepatocellular carcinoma.
Xu Y; Liu R
Heliyon; 2022 Sep; 8(9):e10612. PubMed ID: 36158075
[TBL] [Abstract][Full Text] [Related]
15. Systematic Review and Meta-analysis: Association of Aspirin With Incidence of Hepatocellular Carcinoma.
Zhou X; Zhang T; Sun Y; Li C; Ding X; Zhu Y; Li L; Fan Z
Front Pharmacol; 2022; 13():764854. PubMed ID: 35300300
[No Abstract] [Full Text] [Related]
16. Aspirin for the prevention of hepatocellular carcinoma: an updated meta-analysis with particular focus on patients with chronic liver disease.
Yi M; Feng X; Peng W; Teng F; Tang Y; Chen Z
Eur J Clin Pharmacol; 2022 Apr; 78(4):647-656. PubMed ID: 35032181
[TBL] [Abstract][Full Text] [Related]
17. Aspirin Induced Glioma Apoptosis through Noxa Upregulation.
Chang CY; Pan PH; Li JR; Ou YC; Wang JD; Liao SL; Chen WY; Wang WY; Chen CJ
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32545774
[TBL] [Abstract][Full Text] [Related]
18. Association of Daily Aspirin Therapy With Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B.
Lee TY; Hsu YC; Tseng HC; Yu SH; Lin JT; Wu MS; Wu CY
JAMA Intern Med; 2019 May; 179(5):633-640. PubMed ID: 30882847
[TBL] [Abstract][Full Text] [Related]
19. Aspirin in combination with TACE in treatment of unresectable HCC: a matched-pairs analysis.
Li JH; Wang Y; Xie XY; Yin X; Zhang L; Chen RX; Ren ZG
Am J Cancer Res; 2016; 6(9):2109-2116. PubMed ID: 27725915
[TBL] [Abstract][Full Text] [Related]
20. AMPK-mediated up-regulation of mTORC2 and MCL-1 compromises the anti-cancer effects of aspirin.
Gao M; Kong Q; Hua H; Yin Y; Wang J; Luo T; Jiang Y
Oncotarget; 2016 Mar; 7(13):16349-61. PubMed ID: 26918349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
